AI plus digital pathology and clinical data pinpoint HR+/HER2- early breast cancers with unexpectedly low distant recurrence, sharpening prognosis and guiding endocrine or chemo choices.
Miami Breast Cancer Conference
Tumor board insights reveal how ctDNA-guided ESR1 testing and SERENA-6 strategies may reshape HR+ metastatic breast cancer and local therapy choices.
Advertisement
How GLP-1 weight-loss drugs fit after breast cancer: emerging survival hints, new ESMO cautions during chemo, and smart tapering to avoid rebound.
Real-world community study finds Enhertu in HER2-low metastatic breast cancer has trial-like discontinuation rates; ILD remains key toxicity.
Compare T-DXd, sacituzumab, and dato-DXd in HR+ metastatic breast cancer—key trial results, side effects, and sequencing insights.
New data push ADCs earlier, reshaping HER2+ metastatic breast cancer sequencing, maintenance, and trial strategy.
Advertisement
M. Michele Blackwood, MD, FACS, highlights an innovative trial delivering 1 week of pre-surgery and 2 weeks of post-surgery radiation for patients with breast cancer.
In metastatic triple-negative breast cancer, sacituzumab govitecan was effective and tolerable in the real-world setting.
Elacestrant prolonged progression-free survival in patients with pretreated, ER-positive, HER2-negative breast cancer.
Novel HER2 therapies show strong intracranial efficacy, enabling systemic treatment over local therapy for small, asymptomatic brain metastases in metastatic breast cancer.
New agents targeting endocrine therapy and CDK4/6 resistance in hormone receptor–positive breast cancer are in development.
Kevin Kalinsky, MD, MS, discussed selective estrogen receptor downregulators being explored for the treatment of breast cancer clinical trials.
Tailored treatment available to patients with HER2-positive metastatic breast cancer based on the presence of active central nervous system disease.
In the phase 3 monarchE clinical trial, long-term follow-up results show that the benefit of abemaciclib plus endocrine therapy continued beyond 2 years.
A team-oriented approach based on guideline-directed therapies should be used by clinicians to address patients experiencing cardiotoxicity as a result of their breast cancer, according Jean-Bernard Durand, MD.
Results from 3 clinical trials show that adjuvant CDK4/6 inhibition is a good option for early-stage hormone-receptor-positive breast cancer.
Progress in the treatment of early-stage triple-negative breast cancer includes the now common use of neoadjuvant combinations of immunotherapy with chemotherapy.
Elacestrant demonstrates statistically significant and clinically meaningful improvement in progression-free survival for patients with ER–positive, HER2-negative mBC who previously received CDK4/6 inhibition.
According to real-world research, eribulin may be an effective treatment for patients with metastatic breast cancer who were previously treated with atezolizumab or sacituzumab govitecan.
Sara A. Hurvitz, MD, discusses the pros and cons of anthracycline treatment.
Mohammad Jahanzeb, MD, discusses the designs of landmark trials in early HER2-positive targeted therapy and the adverse events associated with those treatments.
Mark D. Pegram, MD, discusses proposed mechanisms of resistance to HER2-targeted therapies.
Joyce A. O’Shaughnessy, MD, chair of Breast Cancer Research and the Celebrating Women Chair in Breast Cancer at Baylor-Sammons Cancer Center, discusses the ongoing MONARCH and neoMONARCH studies in breast cancer.
According to a retrospective 4.5-year study of patients who had commercial and Medicare supplemental coverage, healthcare resource use and costs remain high among patients with metastatic triple-negative breast cancer.
Elizabeth A. Mittendorf, MD, PhD, discusses the immunotherapy combinations currently being investigated in the treatment of breast cancer.
Kimberly Blackwell, MD, discusses the results of the recent phase III OLYMPIAD trial, which showed olaparib (Lynparza) improved progression-free survival (PFS) versus standard chemotherapy in patients with <em>BRCA</em>-positive breast cancer.
Kelly K. Hunt, MD, professor of Surgery, and chair, Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, discusses incorporating biologic factors into breast cancer staging.
Hope Rugo, MD, a professor of Medicine and director of the Breast Oncology Clinical Trials Program at the UCSF Helen Diller Family Comprehensive Cancer Center, discusses targeting the androgen receptor in breast cancer.
The addition of CDK4/6 and mTOR inhibitors to standard endocrine therapy has significantly improved outcomes in patients with hormone receptor (HR)–positive, HER2-negative advanced breast cancer.
Larry Norton, MD, says the so-called butterfly effect, in which a small creature can cause something on the scale of an earthquake merely by flapping its wings, is fodder for debate on whether the digital revolution in medicine can deliver on its promise for precision medicine.